DEFENSIN THERAPEUTICS ApS: Financial statements 2015
CVR: 35513280
Source: annual report 2015, Danish Business Authority
01/01/2015 – 31/12/2015
DEFENSIN THERAPEUTICS ApS (CVR 35513280) has filed annual accounts for 2015. In 2015, the company reported a net result of DKK -811,429. Equity in the 2015 report amounted to DKK -53,334.
- Profit/Loss
- DKK -811,429
- Equity
- DKK -53,334
- Total Assets
- DKK 242,409
Official annual report
How creditworthy is DEFENSIN THERAPEUTICS ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2015
As of December 10, 2015, Peter Hviid Nordkild has joined the board of directors of DEFENSIN THERAPEUTICS ApS.
As of December 10, 2015, Ejner Bech Jensen has joined the board of directors of DEFENSIN THERAPEUTICS ApS.
As of December 10, 2015, Søren Neve has joined the board of directors of DEFENSIN THERAPEUTICS ApS.
As of December 10, 2015, Matthew Alister Cooper has joined the board of directors of DEFENSIN THERAPEUTICS ApS.
As of December 10, 2015, Jan Wehkamp has joined the board of directors of DEFENSIN THERAPEUTICS ApS.
As of August 27, 2015, NOVOZYMES A/S is registered as an owner of DEFENSIN THERAPEUTICS ApS with an ownership share of 15%.
As of August 27, 2015, PN INVESTMENT ApS is registered as an owner of DEFENSIN THERAPEUTICS ApS with an ownership share of 33%.
As of August 27, 2015, NEVE INVEST ApS is registered as an owner of DEFENSIN THERAPEUTICS ApS with an ownership share of 15%.
As of August 27, 2015, is registered as an owner of DEFENSIN THERAPEUTICS ApS with an ownership share of 15%.
DEFENSIN THERAPEUTICS ApS has published its interim report for the period October 6, 2013 to December 31, 2014.
About DEFENSIN THERAPEUTICS ApS
DEFENSIN THERAPEUTICS ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2013. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Peter Hviid Nordkild. The board consists of Ejner Bech Jensen (chair), Matthew Alister Cooper, Peter Hviid Nordkild and Robert Ehehalt. The company's owners include NOVOZYMES A/S, PN INVESTMENT ApS and NEVE INVEST ApS. The company has 0 employees (2018). In 2025, the company reported a gross profit of DKK -538,913 and a net result of DKK -539,063 compared with DKK -130,534 the year before. Equity in the 2025 report amounted to DKK 774,437.